DOCSLIB.ORG

Supplementary File 2. Symptomatic Drugs Assigned to ALS Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary File 2. Symptomatic Drugs Assigned to ALS Treatment Supplementary material J Neurol Neurosurg Psychiatry Supplementary file 2. Symptomatic drugs assigned to ALS treatment Rank Drugs assigned to Number and Disease Anticho- Antide- Spasmo- Benzo- Non- Opioid Cramp- Hypnotic Anticon- Prokinetic Parkinson Broncho- Psycho- Over- Choli- ALS treatment percentage of modifying linergic pressant lytic diazep- opioid drugs reducing drugs vulsant and drugs lytic leptic active nergic patients using drugs drugs drugs drugs ines analgesic drugs drugs laxative drugs drugs bladder drugs the drug drugs drugs drugs n % Disease Sialorrhea Emotional Spasticity Anxiety, Mild to Moderate Muscle Insomnia Neuro- Reflux, Hypo- Bronchial Agitation, Overactive Bulbar- modifi- lability or restless- moderate to severe cramps pathic flatulence, kinesia, secretion psychosis urinary motor- cation depression ness, pain pain, and pain and consti- restless and bladder deficits palliation palliation fascilu- fascicu- pation legs obstruction from from lations lations syndrom dyspnea dyspnea or or palliative palliative sedation sedation 1 Riluzol 2219 92.8 2219 2 Mirtazapine 417 17.4 417 3 Ipratropiumbromide 412 17.2 412 4 Pirenzepine 384 16.1 384 5 Citalopram 377 15.8 377 6 Lorazepam 365 15.3 365 7 Baclofen 264 11.0 264 8 Metamizole, 252 10.5 252 9 Quinine 215 9.0 215 10 Fentanyl 206 8.6 206 11 THC:CBD 171 7.1 171 12 Amitriptyline 170 7.1 170 170 13 Atropine 148 6.2 148 14 Zopiclone 139 5.8 139 Dextromethorphan/ 15 138 5.8 138 quinidine 16 4-Aminopyridine 102 4.3 102 17 Scopolamine 102 4.3 102 18 Levodopa 77 3.2 77 19 Pregabalin 75 3.1 75 20 Polyethylene glycol 72 3.0 72 21 THC 71 3.0 71 22 Zolpidem 61 2.6 61 23 Diclofenac 60 2.5 60 24 Botulinumtoxin 60 2.5 29 31 25 Ibuprofen 57 2.4 57 26 Acetylcysteine 56 2.3 56 27 Escitalopram 51 2.1 51 28 Pyridostigmine 48 2.0 48 29 Bornaprine 42 1.8 42 30 Tizanidine 41 1.7 41 Meyer T, et al. J Neurol Neurosurg Psychiatry 2020; 91:783–785. doi: 10.1136/jnnp-2020-322938 Supplementary material J Neurol Neurosurg Psychiatry 31 Oxybutynine 41 1.7 41 32 Oxycodone 38 1.6 38 33 Gabapentin 36 1.5 36 34 Tilidine 36 1.5 36 35 Melperone 28 1.2 28 36 Tramadol 26 1.1 26 37 Etoricoxib 23 0.9 23 38 Morphine 21 0.9 21 39 Domperidone 19 0.8 19 40 Codeine 18 0.8 18 41 Opipramol 18 0.8 18 42 Diazepam 15 0.6 15 43 Metoclopramid 14 0.6 14 44 Olanzapine 14 0.6 14 45 Carbamazepine 13 0.5 13 46 Venlafaxine 13 0.5 13 47 Ambroxol 12 0.5 12 48 Sertraline 12 0.5 12 49 Tapentadol 12 0.5 12 50 Tolperison 12 0.5 12 51 Agomelatine 11 0.5 11 11 52 Quetiapine 11 0.5 11 53 Carbomer 10 0.4 10 54 Dimeticone 10 0.4 10 55 Salbutamol 10 0.4 56 Duloxetine 9 0.4 9 10 57 Promethazine 9 0.4 9 58 Melatonin 8 0.3 8 59 Pramipexol 8 0.3 8 60 Rotigotine 8 0.3 8 61 Trospium 8 0.3 8 62 Tyloxapol 8 0.3 8 63 Butylscopolamine 7 0.3 7 64 Paroxetine 7 0.3 7 65 Trimipramine 7 0.3 7 66 Ropinirole 6 0.3 6 67 Clonazepam 6 0.3 5 68 Dantrolene 5 0.2 5 69 Doxepin 5 0.2 5 70 Hydromorphone 5 0.2 5 71 Simeticone 5 0.2 5 72 Buprenorphine 4 0.2 4 73 Bupropion 4 0.2 4 74 Levetiracetam 4 0.2 4 75 Methocarbamol 4 0.2 4 Meyer T, et al. J Neurol Neurosurg Psychiatry 2020; 91:783–785. doi: 10.1136/jnnp-2020-322938 Supplementary material J Neurol Neurosurg Psychiatry 76 Midazolam 4 0.2 4 77 Paracetamol 4 0.2 4 78 Dihydrocodeine 3 0.1 3 79 Oxazepam 3 0.1 3 80 Pipamperone 3 0.1 3 81 Reboxetine 3 0.1 3 82 Bisacodyl 2 0.1 2 83 Brotizolam 2 0.1 2 84 Celecoxib 2 0.1 2 85 Clomipramine 2 0.1 2 Glycopyrronium- 86 2 0.1 2 bromide 87 Nitrazepam 2 0.1 2 88 Chloral Hydrate 1 <0.1 1 89 Clobazam 1 <0.1 1 90 Clozapine 1 <0.1 1 91 Darifenacin 1 <0.1 1 92 Fluoxetine 1 <0.1 1 93 Fluvoxamine 1 <0.1 1 94 Lormetazepam 1 <0.1 1 95 Medazepam 1 <0.1 1 96 Nortriptyline 1 <0.1 1 97 Perazine 1 <0.1 1 98 Perphenazine 1 <0.1 1 99 Prucalopride 1 <0.1 1 100 Zaleplon 1 <0.1 1 101 Edaravone 65 2.7 68 Total, n 2392 2284 1289 1253 701 400 398 369 215 210 128 123 99 95 73 57 48 Total, % 100% 95.5% 53.9% 52.4% 29.3% 16.7% 16.6% 15.4% 9.0% 8.8% 5.4% 5.1% 4.1% 4.0% 3.1% 2.4% 2.0% THC:CBD = Tetrahydrocannabinol:Cannabidiol; THC =Tetrahydrocannabinol, n = number of patients Meyer T, et al. J Neurol Neurosurg Psychiatry 2020; 91:783–785. doi: 10.1136/jnnp-2020-322938.
Load more

Recommended publications
  • Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
    Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review (TCR) March 7, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. March 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2019 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) alosetron (Lotronex®)1 generic, .
    [Show full text]
  • Symptomatic Pharmacotherapy in ALS: Data Analysis from a Platform-Based Medication Management Programme
    PostScript J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-322938 on 21 April 2020. Downloaded from LETTER during the observation. Riluzole was ALS were provided with a mean number the drug most commonly used (93% of 3.2 symptomatic drugs. However, of patients; n=2219). Symptomatic the number of drugs per patient varied Symptomatic pharmacotherapy drugs were assorted to pharmacological substantially (figure 1D). Furthermore, in ALS: data analysis from a domains and to the attainment of treat- we identified an increasing number of ment goals (figure 1B). An overview prescribed drugs per patient in correla- platform- based medication and ranking of symptomatic drugs are tion to advanced stages of King’s clinical management programme summarised in the online supplementary stages of ALS (figure 1C).4 file 2. Based on the number of patients who received the drug, the following top INTRODUCTION 10 symptomatic medicines were identi- DISCUSSION Although symptomatic medicines fied (in decreasing order): mirtazapine, The symptomatic medication was anal- constitute an important intervention ipratropium bromide, pirenzepine, ysed at specialised ALS centres in in amyotrophic lateral sclerosis (ALS), citalopram, lorazepam, baclofen, metam- Germany collaborating on multidisci- few systematic investigations into drug izole, quinine, fentanyl and tetrahydro- plinary managed care. Data assessment management have been reported so far.1 cannabinol:cannabidiol. Patients with was facilitated by the common use of Furthermore, symptomatic pharmaco- therapy is constantly evolving with an increasing number of drugs being used. Therefore, more detailed information on drug prescription must be obtained to monitor the current standards of care, identify potential shortcomings in drug management and elucidate progress in symptomatic pharmacotherapy.
    [Show full text]
  • THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
    VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction Pathophysiology/Etiology to that observed in dogs. It can be The moving topic of this Vet Talk As with most diseases in the veteri- due to a trichobezoar, dehydration, newsletter will be prokinetic medica- nary world, the etiology and patho- obesity, old age, diabetes, immobility, tions. The availability of information physiology of constipation are varied pain from trauma to the low back, on the many prokinetic agents is var- depending on the species being dis- bladder infection, or an anal sac infec- ied at best so an overall consensus of cussed, where in their gastrointestinal tion. In cases that are more chronic, prokinetic medications will be as- tract the problem is occurring, and underlying disease such as colitis or sessed in this article, hopefully giving any accompanying comorbid condi- Irritable Bowel Syndrome (IBS) may better insight to practitioners about tions. be the culprit. On the other hand, the which agents to use in their patients. cause may be idiopathic which is Canines: In man’s best friend, consti- frustrating for both veterinarian and Prevalence pation has many origins. A dog’s patient since this form is most diffi- Chronic constipation and gastroin- digestive tract itself is complex but cult to treat. testinal stasis are highly debilitating ultimately the mass movements and conditions that not only affect human haustral contractions from the large Equines: Despite their large size, patients but our four legged patients intestine (colon), propel feces into the horses have incredibly delicate diges- as well! Though this condition is rectum stimulating the internal anal tive systems.
    [Show full text]
  • Keeping up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A
    Keeping Up with FDA Drug Approvals: 60 New Drugs in 60 Minutes Elizabeth A. Shlom, PharmD, BCPS Senior Vice President & Director Clinical Pharmacy Program | Acurity, Inc. Privileged and Confidential April 10, 2019 Privileged and Confidential Program Objectives By the end of the presentation, the pharmacist or pharmacy technician participant will be able to: ▪ Identify orphan drugs and first-in-class medications approved by the FDA in 2018. ▪ List five new drugs and their indications. ▪ Identify the place in therapy for three novel monoclonal antibodies. ▪ Discuss at least two new medications that address public health concerns. Dr. Shlom does not have any conflicts of interest in regard to this presentation. Both trade names and generic names will be discussed throughout the presentation Privileged and Confidential 2018 NDA Approvals (NMEs/BLAs) ▪ Lutathera (lutetium Lu 177 dotatate) ▪ Braftovi (encorafenib) ▪ Vizimpro (dacomitinib) ▪ Biktarvy (bictegravir, emtricitabine, ▪ TPOXX (tecovirimat) ▪ Libtayo (cemiplimab-rwic) tenofovir, ▪ Tibsovo (ivosidenib) ▪ Seysara (sarecycline) alafenamide) ▪ Krintafel (tafenoquine) ▪ Nuzyra (omadacycline) ▪ Symdeko (tezacaftor, ivacaftor) ▪ Orilissa (elagolix sodium) ▪ Revcovi (elapegademase-lvir) ▪ Erleada (apalutamide) ▪ Omegaven (fish oil triglycerides) ▪ Tegsedi (inotersen) ▪ Trogarzo (ibalizumab-uiyk) ▪ Mulpleta (lusutrombopag) ▪ Talzenna (talazoparib) ▪ Ilumya (tildrakizumab-asmn) ▪ Poteligeo (mogamulizumab-kpkc) ▪ Xofluza (baloxavir marboxil) ▪ Tavalisse (fostamatinib disodium) ▪ Onpattro (patisiran)
    [Show full text]
  • The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders
    The Pharmacology of ProkineticAgents IJGE Issue 4 Vol 1 2003 Review Article The Pharmacology of Prokinetic Agents and Their Role in the Treatment of Gastrointestinal Disorders George Y. Wu, M.D, Ph.D. INTRODUCTION Metoclopramide Normal peristalsis of the gut requires complex, coordinated neural and motor activity. Pharmacologic Category : Gastrointestinal Abnormalities can occur at a number of different Agent. Prokinetic levels, and can be caused by numerous etiologies. This review summarizes current as well as new Symptomatic treatment of diabetic gastric agents that show promise in the treatment of stasis gastrointestinal motility disorders. For these Gastroesophageal reflux e conditions, the most common medications used in s Facilitation of intubation of the small the US are erythromycin, metoclopramide, and U intestine neostigmine (in acute intestinal pseudo- Prevention and/or treatment of nausea and obstruction). A new prokinetic agent, tegaserod, vomiting associated with chemotherapy, has been recently approved, while other serotonin radiation therapy, or post-surgery (1) agonist agents (prucalopride, YM-31636, SK-951, n ML 10302) are currently undergoing clinical o Blocks dopamine receptors in chemoreceptor i t studies. Other prokinetics, such as domperidone, c trigger zone of the CNS (2) A are not yet approved in the US, although are used in f Enhances the response to acetylcholine of o other countries. tissue in the upper GI tract, causing enhanced m s i n motility and accelerated gastric emptying a DELAYED GASTRIC EMPTYING OR h without stimulating gastric, biliary, or c G A S T R O E S O P H A G E A L R E F L U X e pancreatic secretions.
    [Show full text]
  • Marketing Authorisations Granted in December 2020
    Marketing authorisations granted in December 2020 PL Number Grant Date MA Holder Licensed Name(s) Active Ingredient Quantity Units Legal Status Territory PL 14251/0100 01/12/2020 MANX HEALTHCARE LIMITED COLCHICINE 500 MICROGRAMS TABLETS COLCHICINE 0.500 MILLIGRAMS POM UK PL 34424/0050 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 25MG FILM-COATED TABLETS SPIRONOLACTONE 25 MILLIGRAMS POM UK PL 34424/0051 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 50MG FILM-COATED TABLETS SPIRONOLACTONE 50 MILLIGRAMS POM UK PL 34424/0052 02/12/2020 KEY PHARMACEUTICALS LIMITED SPIRONOLACTONE 100MG FILM-COATED TABLETS SPIRONOLACTONE 100 MILLIGRAMS POM UK PL 36282/0021 03/12/2020 RIA GENERICS LIMITED COLCHICINE 500 MICROGRAM TABLETS COLCHICINE 500 MICROGRAMS POM UK PL 39352/0439 03/12/2020 KOSEI PHARMA UK LIMITED FROVATRIPTAN 2.5 MG FILM-COATED TABLETS FROVATRIPTAN SUCCINATE MONOHYDRATE 2.5 MILLIGRAMS POM UK PL 31750/0174 04/12/2020 SUN PHARMACEUTICAL INDUSTRIES EUROPE BV CETRORELIX SUN 0.25 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE CETRORELIX ACETATE 0.25 MILLIGRAMS PER MILLILITRE POM UK PL 34424/0054 04/12/2020 KEY PHARMACEUTICALS LIMITED ALIMEMAZINE TARTRATE 10MG FILM COATED TABLETS ALIMEMAZINE TARTRATE 10.00 MILLIGRAMS POM UK PL 17780/0858 07/12/2020 ZENTIVA PHARMA UK LIMITED FINGOLIMOD ZENTIVA 0.5 MG HARD CAPSULES FINGOLIMOD HYDROCHLORIDE 0.56 MILLIGRAMS POM UK PL 01502/0113 08/12/2020 HAMELN PHARMA LTD AMIODARONE HYDROCHLORIDE 20 MG/ML SOLUTION FOR INFUSION AMIODARONE HYDROCHLORIDE 20 MILLIGRAMS POM UK PL 16786/0006 08/12/2020
    [Show full text]
  • Prucalopride (SHP555) Update for Global Investors
    Prucalopride (SHP555) Update for Global Investors March 7, 2018 STATEMENTS REGARDING PRUCALOPRIDE SUBJECT TO REGULATORY APPROVAL - INTENDED FOR INVESTOR AUDIENCE ONLY Prucalopride - Introduction U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation (CIC) • Prucalopride is an investigational product for the treatment of chronic idiopathic constipation in adults in the U.S. • The product is investigational. The U.S. FDA accepted submission of Shire’s NDA and the PDUFA date is on or around December 21, 2018 • Shire does not know when or if FDA will approve prucalopride • Shire cannot predict the content of the labeling for prucalopride in the event of FDA approval • This presentation updates investors on Shire’s current development plan for prucalopride 2 STATEMENTS REGARDING PRUCALOPRIDE SUBJECT TO REGULATORY APPROVAL - INTENDED FOR INVESTOR AUDIENCE ONLY Prucalopride - Summary U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation (CIC) • Reinforces Shire’s long-standing heritage in gastrointestinal (GI) conditions and deep customer relationships and in-house capabilities • Strong addition to GI franchise, which includes LIALDA, GATTEX and provides bridge to pipeline assets such as SHP621 and SHP647 • If approved, prucalopride will be the only readily available 5-HT4 agonist1 in the U.S. to treat CIC in adults • CIC affects an estimated 35 million people in the U.S.2,3* Many patients are dissatisfied with or do not respond to current therapies4 • Efficacy and safety evaluated in five main Phase 3 and one Phase 4 double-blind, placebo-controlled clinical trials5,6 • NDA submission includes real-world evidence from an observational, pharmacoepidemiology cardiovascular safety study7 *This represents ~14% of the U.S.
    [Show full text]
  • Gastroparesis: 2014
    GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #1 Richard W. McCallum, MD, FACP, FRACP (Aust), FACG Status of Pharmacologic Management of Gastroparesis: 2014 Richard W. McCallum Joseph Sunny, Jr. Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction of the gastric outlet or small intestine. The main etiologies are diabetes, idiopathic and post- gastric and esophageal surgical settings. The management of gastroparesis is challenging due to a limited number of medications and patients often have symptoms, which are refractory to available medications. This article reviews current treatment options for gastroparesis including adverse events and limitations as well as future directions in pharmacologic research. INTRODUCTION astroparesis is a syndrome characterized by documented gastroparesis are increasing.2 Physicians delayed emptying of gastric contents without have both medical and surgical approaches for these Gmechanical obstruction of the stomach, pylorus or patients (See Figure 1). Medical therapy includes both small bowel. Patients can present with nausea, vomiting, prokinetics and antiemetics (See Table 1 and Table 2). postprandial fullness, early satiety, pressure, fullness The gastroparesis population will grow as diabetes and abdominal distension. In addition, abdominal pain increases and new therapies will be required. What located in the epigastrium, and distinguished from the do we know about the size of the gastroparetic term discomfort, is increasingly being recognized population? According to a study from the Mayo Clinic as an important symptom. The main etiologies of group surveying Olmsted County in Minnesota, the gastroparesis are diabetes, idiopathic, and post gastric risk of gastroparesis in Type 1 diabetes mellitus was and esophageal surgeries.1 Hospitalizations from significantly greater than for Type 2.
    [Show full text]
  • Zelnorm Page: 1 of 5
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.25 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Gastrointestinal Agents Original Policy Date: April 26, 2019 Subject: Zelnorm Page: 1 of 5 Last Review Date: March 13, 2020 Zelnorm Description Zelnorm (tegaserod) Background Zelnorm is an agonist of serotonin type-4 (5-HT4) receptors that stimulates the peristaltic reflex and intestinal secretion, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract (1). Regulatory Status FDA-approved indication: Zelnorm is a serotonin-4 (5-HT4) receptor agonist indicated for treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C) (1). Limitations of Use: The safety and effectiveness of Zelnorm in men with IBS-C have not been established (1). Zelnorm is contraindicated in patients with: (1) 1. A history of myocardial infarction (MI), stroke, transient ischemic attack (TIA), or angina. 2. A history of ischemic colitis or other forms of intestinal ischemia. 3. Severe renal impairment (eGFR < 15 mL/min/1.73 m2) or end-stage renal disease. 4. Moderate and severe hepatic impairment (Child-Pugh B or C). 5. A history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi Dysfunction, or abdominal adhesions. 5.50.25 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Gastrointestinal Agents Original Policy Date: April 26, 2019 Subject: Zelnorm Page: 2 of 5 The safety and effectiveness of Zelnorm in pediatric patients less than 18 years of age have not been established (1).
    [Show full text]
  • WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/074683 Al 19 May 2016 (19.05.2016) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/DK20 15/050343 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 11 November 2015 ( 11. 1 1.2015) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: PA 2014 00655 11 November 2014 ( 11. 1 1.2014) DK (84) Designated States (unless otherwise indicated, for every 62/077,933 11 November 2014 ( 11. 11.2014) US kind of regional protection available): ARIPO (BW, GH, 62/202,3 18 7 August 2015 (07.08.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: LUNDORF PEDERSEN MATERIALS APS TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DK/DK]; Nordvej 16 B, Himmelev, DK-4000 Roskilde DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (DK).
    [Show full text]
  • Esophageal and Gastric Motility Disorders: a Case Based Approach
    Esophageal and Gastric Motility Disorders: A case based approach Gokul Balasubramanian, MD Assistant Professor Director of Gastrointestinal Motility Lab Division of Gastroenterology, Hepatology and Nutrition The Ohio State University Wexner Medical Center Conflicts of Interest: • None 1 Overview • Esophageal anatomy • Dysphagia-case based approach • Reflux disease-case based approach • Gastric physiology • Gastroparesis-case based approach Dysphagia-Case based approach 2 Esophagus: Anatomy • 25 cm muscular tube. • Extends from upper esophageal sphincter to stomach. • Proximal 1/3rd consist of striated muscles while distal 2/3rd is formed by smooth muscles. • Lined squamous epithelium. Terminology • Dysphagia: derived from the Greek word dys (difficulty, disordered) and phagia (to eat). • Odynophagia: painful swallowing. • Globus Sensation: Sensation of lump in throat between meals. 3 History Oropharyngeal Esophageal • Oral: • Food stuck in ‒ Drooling of saliva suprasternal notch or ‒ Food spillage retrosternal region ‒ Sialorrhea ‒ Piecemeal swallows • Motility: ‒ Associated dysarthria ‒ dysphagia to solids and liquids • Pharyngeal: ‒ Associated with ‒ Choking/cough during heartburn or chest pain. swallow ‒ Associated dysphonia • Mechanical: ‒ progressive dysphagia to solids; may involve liquids at later stages Dysphagia Assessment Fluoroscopic examination Endoscopic Manometric examination examination 4 Case Study 1: 78-year-old female with no significant medical history presenting with: ‒ Dysphagia to both solids and liquids ‒ Chest pain ‒ Denies any heartburn ‒ 50 lb weight loss • Epiphrenic diverticulum • Epiphrenic diverticulum • Resistance at GEJ • Beaking at GEJ Case Study 1: • Mean DCI:2380 • Mean LES IRP:32 mm Hg • Mean DL: 3.8 sec 5 Case Study 1: • Post extended myotomy and diverticulectomy • Fairly doing Achalasia • Rare esophageal motility disorder • Esophageal aperistalsis • Impaired LES relaxation Loss of inhibitory neurons secreting VIP and NO leads to unopposed excitatory activity and failure of LES relaxation DA Patel.
    [Show full text]
  • MT H 0334 002 PAR.Pdf
    CMDh/305/2013 March 2018, Rev.02 Summary Public Assessment Report Generics Prucalopride Dexcel 1 mg film-coated tablets Prucalopride Dexcel 2 mg film-coated tablets [Prucalopride (as Succinate)] MT/H/0334/001-002/DC Date: 20th January 2020 Summary Public Assessment Report Generics Prucalopride Dexcel 1 mg film-coated tablets Prucalopride Dexcel 2 mg film-coated tablets Prucalopride 1 mg, 2mg film-coated tablets This is a summary of the public assessment report (PAR) for Prucalopride Dexcel 1 mg, 2mg film-coated tablets. It explains how Prucalopride Dexcel 1 mg, 2mg film-coated tablets was assessed and its authorisation recommended as well as its conditions of use. It is not intended to provide practical advice on how to use Prucalopride Dexcel 1 mg, 2mg film-coated tablets. For practical information about using Prucalopride Dexcel 1 mg, 2mg film-coated tablets, patients should read the package leaflet or contact their doctor or pharmacist. What is Prucalopride Dexcel 1 mg, 2mg film-coated tablets and what is it used for? Prucalopride Dexcel 1 mg, 2mg film-coated tablets is a ‘generic medicine’. This means that Prucalopride Dexcel 1 mg, 2mg film-coated tablets is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Resolor 1mg, 2mg film coated tablets. Prucalopride is used for the treatment of chronic constipation in adults in whom laxatives do not work well enough. Not for use in children and adolescents younger than 18 years. How does Prucalopride Dexcel 1 mg, 2mg film-coated tablets work? Prucalopride Dexcel belongs to a group of gut motility enhancing medicines (gastrointestinal prokinetics).
    [Show full text]